Home › Companies › SUTRO BIOPHARMA INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and SUTRO BIOPHARMA INC.’s Form 8-K, filed June 10, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 6, 2025: 6 items on SUTRO BIOPHARMA INC.’s Form 8-K, filed June 10, 2025: 6 passed (calculated).
Significant dissent: 3 directors (43.9%, 43.3%, 43.3% against).
Notable dissent: 1 say-on-pay vote (77.7% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13F, 1.3%, as of September 30, 2026)
Explore SUTRO BIOPHARMA INC. in the interactive database Compare manager voting policies
These tallies are SUTRO BIOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Heidi Hunter | 31,491,009 | -- | -- | 24,026,714 | 12,503,128 | 57% | Passed (calculated) | — |
| Elect Director: Jon Wigginton | 31,496,677 | -- | -- | 24,021,046 | 12,503,128 | 57% | Passed (calculated) | — |
| Elect Director: Michael Dybbs | 31,145,398 | -- | -- | 24,372,325 | 12,503,128 | 56% | Passed (calculated) | — |
| 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 67,419,553 | 203,267 | 398,031 | -- | -- | 99.7% | Passed (calculated) | — |
| 3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting | 42,988,166 | 12,355,370 | 174,187 | -- | 12,503,128 | 78% | Passed (calculated) | — |
| 4. Approval of the amendment of the Company's Restated Certificate of Incorporation (the " Charter ") to effect a reverse stock split of the Company's outstanding shares of common stock at a ratio of any whole number between 1-for-5 and 1-for-25, with the exac | 57,705,935 | 10,131,760 | 183,156 | -- | -- | 85% | Passed (calculated) | — |
Source: SUTRO BIOPHARMA INC., Form 8-K, filed with the SEC on June 10, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
109 asset managers disclosed a vote on at least one SUTRO BIOPHARMA INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
57% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Heidi Hunter
SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Heidi Hunter”): 31,491,009 for, 24,026,714 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 57% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 12,070,917 for, 734,838 withheld, 185,747 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,577,342 | 0 | 0 | 0 | For |
| BlackRock | 3,456,173 | 0 | 0 | 0 | For |
| Fidelity | 1,696,246 | 0 | 0 | 500 | For |
| Goldman Sachs | 890,665 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 395,450 | Withhold |
| Equitable | 151,381 | 0 | 0 | 96,370 | Mixed |
| Prudential/PGIM | 226,000 | 0 | 0 | 14,430 | Mixed |
| TIAA | 234,550 | 0 | 0 | 0 | For |
| Charles Schwab | 199,901 | 0 | 0 | 0 | For |
| Nationwide | 156,463 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 149,383 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 136,623 | 0 | Abstain |
| Aberdeen | 0 | 0 | 0 | 69,389 | Withhold |
| Lincoln Financial | 60,700 | 0 | 0 | 2,078 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 61,267 | Withhold |
| Global X | 48,431 | 0 | 0 | 0 | For |
| Invesco | 45,692 | 0 | 0 | 0 | For |
| Pacific Life | 44,834 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 40,104 | Withhold |
| Bridge Builder Trust | 36,575 | 0 | 0 | 0 | For |
| Northern Trust | 31,730 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 31,500 | 0 | Abstain |
| Voya | 24,466 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 19,884 | Withhold |
| Jackson National | 0 | 0 | 17,624 | 0 | Abstain |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
57% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Jon Wigginton, M.D.
SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Jon Wigginton”): 31,496,677 for, 24,021,046 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 57% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 12,070,917 for, 734,838 withheld, 185,747 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,577,342 | 0 | 0 | 0 | For |
| BlackRock | 3,456,173 | 0 | 0 | 0 | For |
| Fidelity | 1,696,246 | 0 | 0 | 500 | For |
| Goldman Sachs | 890,665 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 395,450 | Withhold |
| Equitable | 151,381 | 0 | 0 | 96,370 | Mixed |
| Prudential/PGIM | 226,000 | 0 | 0 | 14,430 | Mixed |
| TIAA | 234,550 | 0 | 0 | 0 | For |
| Charles Schwab | 199,901 | 0 | 0 | 0 | For |
| Nationwide | 156,463 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 149,383 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 136,623 | 0 | Abstain |
| Aberdeen | 0 | 0 | 0 | 69,389 | Withhold |
| Lincoln Financial | 60,700 | 0 | 0 | 2,078 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 61,267 | Withhold |
| Global X | 48,431 | 0 | 0 | 0 | For |
| Invesco | 45,692 | 0 | 0 | 0 | For |
| Pacific Life | 44,834 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 40,104 | Withhold |
| Bridge Builder Trust | 36,575 | 0 | 0 | 0 | For |
| Northern Trust | 31,730 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 31,500 | 0 | Abstain |
| Voya | 24,466 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 19,884 | Withhold |
| Jackson National | 0 | 0 | 17,624 | 0 | Abstain |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
56% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Michael Dybbs, Ph.D.
SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Michael Dybbs”): 31,145,398 for, 24,372,325 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 56% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 12,039,187 for, 766,568 withheld, 185,747 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,577,342 | 0 | 0 | 0 | For |
| BlackRock | 3,456,173 | 0 | 0 | 0 | For |
| Fidelity | 1,696,246 | 0 | 0 | 500 | For |
| Goldman Sachs | 890,665 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 395,450 | Withhold |
| Equitable | 151,381 | 0 | 0 | 96,370 | Mixed |
| Prudential/PGIM | 226,000 | 0 | 0 | 14,430 | Mixed |
| TIAA | 234,550 | 0 | 0 | 0 | For |
| Charles Schwab | 199,901 | 0 | 0 | 0 | For |
| Nationwide | 156,463 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 149,383 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 136,623 | 0 | Abstain |
| Aberdeen | 0 | 0 | 0 | 69,389 | Withhold |
| Lincoln Financial | 60,700 | 0 | 0 | 2,078 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 61,267 | Withhold |
| Global X | 48,431 | 0 | 0 | 0 | For |
| Invesco | 45,692 | 0 | 0 | 0 | For |
| Pacific Life | 44,834 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 40,104 | Withhold |
| Bridge Builder Trust | 36,575 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 31,730 | Withhold |
| John Hancock | 0 | 0 | 31,500 | 0 | Abstain |
| Voya | 24,466 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 19,884 | Withhold |
| Jackson National | 0 | 0 | 17,624 | 0 | Abstain |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To approve an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock at a ratio of any whole number between 1-for-5 and 1-for-25, with the exact ratio determined by the board of directors in its discretion, subject to the board of directors authority to abandon such amendment.
SUTRO BIOPHARMA INC.’s own tally for this item (“4. Approval of the amendment of the Company's Restated Certificate of Incorporation (the " Charter ") to effect a reverse stock split of the Company's outstanding shares of common stock at a ratio of any whole number bet”): 57,705,935 for, 10,131,760 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 12,991,502 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,577,342 | 0 | 0 | 0 | For |
| BlackRock | 3,456,173 | 0 | 0 | 0 | For |
| Fidelity | 1,696,746 | 0 | 0 | 0 | For |
| Goldman Sachs | 890,665 | 0 | 0 | 0 | For |
| Dimensional | 395,450 | 0 | 0 | 0 | For |
| Equitable | 247,751 | 0 | 0 | 0 | For |
| Prudential/PGIM | 240,430 | 0 | 0 | 0 | For |
| TIAA | 234,550 | 0 | 0 | 0 | For |
| Charles Schwab | 199,901 | 0 | 0 | 0 | For |
| Nationwide | 156,463 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 149,383 | 0 | 0 | 0 | For |
| ETF Series Solutions | 136,623 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 62,778 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,267 | 0 | 0 | 0 | For |
| Global X | 48,431 | 0 | 0 | 0 | For |
| Invesco | 45,692 | 0 | 0 | 0 | For |
| Pacific Life | 44,834 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 40,104 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,575 | 0 | 0 | 0 | For |
| Northern Trust | 31,730 | 0 | 0 | 0 | For |
| John Hancock | 31,500 | 0 | 0 | 0 | For |
| Voya | 24,466 | 0 | 0 | 0 | For |
| ProShares | 19,884 | 0 | 0 | 0 | For |
| Jackson National | 17,624 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Prior year: 99.7% for (June 6, 2024 meeting) ▼ 22.0 pts
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
SUTRO BIOPHARMA INC.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting”): 42,988,166 for, 12,355,370 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,577,342 | 0 | 0 | 0 | For |
| BlackRock | 3,456,173 | 0 | 0 | 0 | For |
| Fidelity | 1,696,746 | 0 | 0 | 0 | For |
| Goldman Sachs | 890,665 | 0 | 0 | 0 | For |
| Dimensional | 0 | 395,450 | 0 | 0 | Against |
| Equitable | 247,751 | 0 | 0 | 0 | For |
| Prudential/PGIM | 226,000 | 14,430 | 0 | 0 | Mixed |
| TIAA | 234,550 | 0 | 0 | 0 | For |
| Charles Schwab | 199,901 | 0 | 0 | 0 | For |
| Nationwide | 156,463 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 149,383 | 0 | 0 | 0 | For |
| ETF Series Solutions | 136,623 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 60,700 | 2,078 | 0 | 0 | For |
| ALPS ETF Trust | 61,267 | 0 | 0 | 0 | For |
| Global X | 48,431 | 0 | 0 | 0 | For |
| Invesco | 0 | 45,692 | 0 | 0 | Against |
| Pacific Life | 44,834 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 40,104 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,575 | 0 | 0 | 0 | For |
| Northern Trust | 31,730 | 0 | 0 | 0 | For |
| John Hancock | 31,500 | 0 | 0 | 0 | For |
| Voya | 24,466 | 0 | 0 | 0 | For |
| ProShares | 19,884 | 0 | 0 | 0 | For |
| Jackson National | 0 | 17,624 | 0 | 0 | Against |
Fund voting reports, all 36 managers: 12,516,228 for, 475,274 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 0 | 7,424,745 | 0 | 0 | Against |
| Kynam Capital Management, LP | 0 | 0 | 0 | 3,684,133 | Withhold |
| RA CAPITAL MANAGEMENT, L.P. | 3,341,169 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 2,292,261 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 2,196,814 | 0 | 0 | 0 | For |
| BlackRock | 2,002,327 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,000,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,905,304 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,685,252 | 0 | 0 | 0 | For |
| State Street | 1,565,359 | 0 | 0 | 0 | For |
| Velan Capital Investment Management LP | 1,030,000 | 0 | 0 | 0 | For |
| AQR | 641,819 | 0 | 0 | 0 | For |
| Prudential/PGIM | 488,660 | 20,100 | 0 | 0 | For |
| DAFNA Capital Management LLC | 0 | 437,079 | 0 | 0 | Against |
| Renaissance | 389,861 | 0 | 0 | 0 | For |
| Northern Trust | 361,231 | 0 | 0 | 0 | For |
| Asset Management One Co., Ltd. | 352,949 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 304,955 | 0 | 0 | 0 | For |
| Goldman Sachs | 297,133 | 0 | 0 | 0 | For |
| Nuveen | 290,897 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 272,532 | 0 | 0 | Against |
| Charles Schwab | 199,901 | 0 | 0 | 0 | For |
| Dimensional | 0 | 162,708 | 0 | 0 | Against |
| STRS OHIO | 152,800 | 0 | 0 | 0 | For |
| Two Sigma | 141,764 | 0 | 0 | 0 | For |
Institutional-manager reports, all 89 managers: 22,709,123 for, 8,437,181 against, 3,684,133 withheld. Showing the 25 largest; every one is in the interactive database (link above).
99.7% Majority: yes · of votes cast
Prior year: 99.8% for (June 6, 2024 meeting) ▼ 0.1 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
SUTRO BIOPHARMA INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 67,419,553 for, 203,267 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 12,991,172 for, 330 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,577,342 | 0 | 0 | 0 | For |
| BlackRock | 3,456,173 | 0 | 0 | 0 | For |
| Fidelity | 1,696,746 | 0 | 0 | 0 | For |
| Goldman Sachs | 890,665 | 0 | 0 | 0 | For |
| Dimensional | 395,450 | 0 | 0 | 0 | For |
| Equitable | 247,751 | 0 | 0 | 0 | For |
| Prudential/PGIM | 240,430 | 0 | 0 | 0 | For |
| TIAA | 234,550 | 0 | 0 | 0 | For |
| Charles Schwab | 199,901 | 0 | 0 | 0 | For |
| Nationwide | 156,463 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 149,383 | 0 | 0 | 0 | For |
| ETF Series Solutions | 136,623 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 62,778 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,267 | 0 | 0 | 0 | For |
| Global X | 48,431 | 0 | 0 | 0 | For |
| Invesco | 45,692 | 0 | 0 | 0 | For |
| Pacific Life | 44,834 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 40,104 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,575 | 0 | 0 | 0 | For |
| Northern Trust | 31,730 | 0 | 0 | 0 | For |
| John Hancock | 31,500 | 0 | 0 | 0 | For |
| Voya | 24,466 | 0 | 0 | 0 | For |
| ProShares | 19,884 | 0 | 0 | 0 | For |
| Jackson National | 17,624 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 84,461,365 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.42% |
| 2 | BlackRock | 4.09% |
| 3 | Fidelity | 2.01% |
| 4 | Goldman Sachs | 1.05% |
| 5 | Dimensional | 0.47% |
| 6 | Equitable | 0.29% |
| 7 | Prudential/PGIM | 0.28% |
| 8 | TIAA | 0.28% |
| 9 | Charles Schwab | 0.24% |
| 10 | Nationwide | 0.19% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 8.79% |
| 2 | Kynam Capital Management, LP | 4.36% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 3.96% |
| 4 | Eversept Partners, LP | 2.71% |
| 5 | Samsara BioCapital, LLC | 2.60% |
| 6 | BlackRock | 2.37% |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.37% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.26% |
| 9 | Vestal Point Capital, LP | 2.00% |
| 10 | State Street | 1.85% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 6,204,784 | 7.35% | Form 13F, quarter ended March 31, 2025 |
| Suvretta Capital Management, LLC | 5,778,188 | 6.84% | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| RA Capital Management, L.P. | 4,434,637 | 5.25% | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| Vanguard Group | 4,395,244 | 5.20% | Form 13F, quarter ended March 31, 2025 |
| William J. Newell | 1,956,313 | 2.32% | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| Goldman Sachs | 1,712,115 | 2.03% | Form 13F, quarter ended March 31, 2025 |
| State Street | 1,682,339 | 1.99% | Form 13F, quarter ended March 31, 2025 |
| Nuveen | 1,323,777 | 1.57% | Form 13F, quarter ended March 31, 2025 |
| BVF PARTNERS L P/IL | 1,251,788 | 1.48% | Schedule 13G, filed February 18, 2026 |
| Affinity Asset Advisors, LLC | 1,069,519 | 1.27% | Schedule 13G, filed May 14, 2026 |
Percentages above are of 84,461,365 shares outstanding, as reported by SUTRO BIOPHARMA INC. on its Form 10-Q dated May 2, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At SUTRO BIOPHARMA INC.'s shareholder meeting held June 6, 2025, in the 2024-2025 proxy season, 109 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 757 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 78% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SUTRO BIOPHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SUTRO BIOPHARMA INC.’s 10-Q dated May 2, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
SUTRO BIOPHARMA INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “SUTRO BIOPHARMA (STRO) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/sutro-biopharma-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.